MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Gastrointestinal problemsm(also see autonomic dysfunction)"

  • 2023 International Congress

    The N6-Methyladenosine mRNA Methylase METTL14 Regulates TLR4-mediated intestinal dysfunction in Parkinson’s Disease

    J. Zou, Z. Deng, ZZ. Lu, L. Wei, LL. Wu, F. Yu (Guangzhou, China)

    Objective: The aim of this study is to explore the function and mechanism of RNA m6A modification in gut-derived inflammation of Parkinson's disease (PD). Background:…
  • 2023 International Congress

    Safety in Levodopa/carbidopa Intestinal Gel (LCGI) titration in the Intensive Care Unit (ICU) setting for Parkinson’s Disease (PD) patient with severe dysphagia

    N. Lopez Ariztegui, G. Tabar Comellas, MI. Morales Casado, D. Rivero Rodriguez, M. Ennazeh, P. Leal Sanz (Toledo, Spain)

    Objective: Describe a PD patient with obsessive-compulsive disorder (OCD) and paranoid symptoms in whom treatment with LCIG was started in the ICU due to severe…
  • 2023 International Congress

    Clinical Improvement and drastic reduction of Equivalent Dose of Levodopa (LEDD) in an Advanced Parkinson’s Disease Patient after Levodopa/Entacapone/Carbidopa Intestinal Gel (LECIG) Treatment

    G. Tabar Comellas, MI. Morales Casado, JC. Segundo-Rodríguez, N. Lopez Ariztegui (Toledo, Spain)

    Objective: Describe a patient in which after starting continuous infusion of LECIG a large reduction of the LEDD  is achieved. Background: Gastroparesis (GP) is one…
  • 2023 International Congress

    Gut microbiota dysbiosis in Parkinson’s disease patients: a potential biomarker of disease severity and progression?

    R. Cerroni, M. Conti, M. Pierantozzi, V. D'Angelo, N. Mercuri, A. Teofani, D. Pietrucci, G. Chillemi, V. Unida, A. Stefani (Rome, Italy)

    Objective: To investigate gut microbiota alterations in Parkinson's disease (PD) along disease progression. Background: Gut microbiota dysbiosis is considered a hallmark in PD1. However, it is…
  • 2023 International Congress

    Efficacy of a four-strain probiotic on gut dysbiosis, motor and non-motor symptoms in Parkinson`s disease: a multicentre randomised controlled trial

    V. Leta, P. Zinzalias, J. Staunton, L. Batzu, D. Trivedi, F. Jernstedt, K. Rosqvist, J. Timpka, T. van Vliet, A. Podlewska, M. Parry, D. van Wamelen, A. Rizos, G. Chung-Faye, A. Borsini, C. Pariante, P. Odin, K. Ray Chaudhuri (London, United Kingdom)

    Objective: To evaluate the effect of a four-strain probiotic (Lacticaseibacillus rhamnosus, Enterococcus faecium, Lactobacillus acidophilus, Lactiplantibacillus plantarum) on gut microbiota composition, motor and non-motor symptoms…
  • 2023 International Congress

    Effect of multi-strain probiotics on gut microbiome and metabolites in Parkinson’s Disease

    JW. Hor, SY. Lim, CW. Chong, SL. Song, CSJ. Teh, TS. Toh, JL. Lim, KY. Khaw, AH. Tan (Kuala Lumpur, Malaysia)

    Objective: We investigated the effects of multi-strain probiotics administration on gut microbiome and metabolites, and markers of intestinal permeability and inflammation. Background: Probiotics have been…
  • 2023 International Congress

    Microbiota and Gastrointestinal Manifestations of Parkinson’s Disease with Arabic Translation of Gastrointestinal Dysfunction Scale

    Y. Salah, N. Dawood, M. Salama, A. Shalash (cairo, Egypt)

    Objective: To investigate the frequency of occurrence of gastrointestinal tract GIT symptoms and their relation to patients’ clinical characteristics in addition the characteristics of gut…
  • 2023 International Congress

    Olfactory neurons’ Substance P is highly expressed in Parkinson’s disease reflecting gastrointestinal dysfunction

    T. Schirinzi, D. Maftei, P. Grillo, R. Bovenzi, J. Bissacco, C. Simonetta, H. Zenuni, FM. Passali, S. Di Girolamo, A. Stefani, NB. Mercuri, R. Lattanzi, C. Severini (Rome, Italy)

    Objective: To elucidate the role of Substance P in PD through molecular characterization of patients’ olfactory neurons. Background: Substance P is a neuropeptide largely expressed…
  • 2023 International Congress

    Dietary protein redistribution influences the efficacy of levodopa/carbidopa intestinal gel (LCIG) infusion

    Y. Ben Mordechai, S. Israeli-Korn, O. Cohen, S. Hassin-Baer (Tel Hashomer, Israel)

    Objective: To compare levodopa/carbidopa intestinal gel (LCIG) with equally distributed dietary protein (Diet_EDP) versus restricted to twice daily (Diet_RP) and Mediterranean diet (Diet_M). Background: Levodopa…
  • 2022 International Congress

    Intestinal microbial dysbiosis promotes prebiotic-reversible inflammation in Parkinson’s disease

    R. Manfready, D. Hall, C. Goetz, A. Keshavarzian (Chicago, USA)

    Objective: To determine the functional effects of disrupted intestinal microbiota in Parkinson’s disease (PD), particularly the impacts of dysbiosis on inflammation, neuroprotective hormone secretion, and…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 11
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley